- Nivolumab and Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults
- Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors
- Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma
- A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
- DAY101 Vs. Standard of Care Chemotherapy in Pediatric Patients with Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
- DAY101 In Gliomas and Other Tumors
All references to “portfolio” on this website refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” on this website refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.